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Hypertension affects more than 1.5 billion people
worldwide but the precise cause of elevated blood
pressure (BP) cannot be determined in most affected
individuals. Nonetheless, blockade of the renin-
angiotensin system (RAS) lowers BP in the majority
of patients with hypertension. Despite its apparent
role in hypertension pathogenesis, the key cellular
targets of the RAS that control BP have not been
clearly identified. Here we demonstrate that RAS
actions in the epithelium of the proximal tubule
have a critical and nonredundant role in determining
the level of BP. Abrogation of AT1 angiotensin
receptor signaling in the proximal tubule alone is
sufficient to lower BP, despite intact vascular
responses. Elimination of this pathway reduces
proximal fluid reabsorption and alters expression of
key sodium transporters, modifying pressure-natri-
uresis and providing substantial protection against
hypertension. Thus, effectively targeting epithelial
functions of the proximal tubule of the kidney should
be a useful therapeutic strategy in hypertension.INTRODUCTION
Among the regulatory systems for blood pressure (BP), the RAS
has a dominant role (Le et al., 2008). Pathological activation of
the RAS is a common contributor to hypertension in humans
as RAS antagonists lower BP in the majority of patients with
essential hypertension (Matchar et al., 2008). The actions of
the RAS to increase BP are primarily mediated by activation of
type 1 (AT1) angiotensin receptors. AT1 receptors are expressed
in a number of tissues where they have a potential to affect BP
including the CNS, heart, vasculature, kidney, and adrenal gland
(Le et al., 2008), but it has been difficult to identify the critical
tissue targets of the RAS in hypertension pathogenesis.CRecent studies have implicated vascular signaling pathways
as key contributors to BP regulation and development of hyper-
tension (Guilluy et al., 2010; Heximer et al., 2003; Michael et al.,
2008; Wirth et al., 2008). On the other hand, the work of Guyton
and colleagues (Guyton, 1991), human genetic studies by the
Lifton laboratory (Lifton et al., 2001), and our recent studies in
mice (Coffman and Crowley, 2008) have suggested that renal
excretory function is a major determinant of intra-arterial pres-
sure. In the kidney, AT1 receptors are expressed in epithelial cells
along the nephron (Bouby et al., 1997). Among populations of
renal epithelia, AT1 receptors in the proximal tubule may have
special relevance to BP homeostasis because this segment is
responsible for reabsorption of a sizeable fraction of the glomer-
ular filtrate (Weinstein, 2008), it contains all of the components of
the RAS under independent local control (Kobori et al., 2007;
Navar et al., 2002), and RAS activation is known to influence
its handling of solutes and fluid (Cogan, 1990). Nonetheless,
while direct actions of angiotensin II in the proximal tubule
were first identified more than 25 years ago (Schuster et al.,
1984), their impact on regulation of BP in the intact animal has
never been clearly defined. Here we demonstrate potent actions
of AT1 receptors in renal proximal tubule to regulate BP
homeostasis.RESULTS
Reduced BP in Mice Lacking AT1A Receptors
in the Renal Proximal Tubule
We crossed mice with a conditional Agtr1a allele (Figure S1,
available online) with a Pepck-Cre transgenic mouse line
expressing Cre in proximal but not distal nephron segments
(Rankin et al., 2006; Figures S2A and S2B) to generatemice lack-
ing AT1A receptors only in the renal proximal tubule (PTKO). As
shown in Figure 1A, systolic BPs measured by radiotelemetry
were significantly lower in PTKOmice (126 ± 3mmHg) than litter-
mate controls (136 ± 3 mm Hg; p = 0.03). This difference was
apparent both during the day (120 ± 3 versus 130 ± 3 mm Hg;
p = 0.003) and at night (133 ± 3 versus 142 ± 3 mm Hg;
p = 0.04). Mice were then sequentially fed high-salt (6% NaCl)
and low-salt (<0.002% NaCl) diets while their BPs wereell Metabolism 13, 469–475, April 6, 2011 ª2011 Elsevier Inc. 469
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Figure 1. Baseline Studies in PTKO Mice
(A) Twelve hours mean systolic BPs during the day (d) and at night (n) on a control diet. Systolic BPs were significantly lower in PTKO mice compared to controls
(*p = 0.03).
(B) BPs increased significantly (yp < 0.01) and to a similar extent in PTKOs and controls during high-salt (6% NaCl) feeding and returned to baseline values on
low-salt (<0.02% NaCl) feeding. BPs were significantly lower in the PTKOs throughout the experiment (*p < 0.044).
(C) The maximal increases in mean arterial pressure (MAP) compared to baseline in response to bolus infusions of angiotensin II (AngII, 1 and 10 mg/kg) or
epinephrine (Epi, 10 mg/kg) were identical between PTKOs and controls.
(D) Rates of fluid reabsorption by the renal PTmeasured in vivo by using standard free-flowmicropuncturewere significantly reduced in the PTKOmice compared
to controls as an absolute rate (p = 0.00011) or (E) when adjusted for single-nephron glomerular filtration rate (p = 0.0007). Error bars represent SEM.
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Angiotensin Receptors in the Renal Proximal Tubulemonitored. As shown in Figure 1B, BPs increased significantly
and to a similar extent in both groups during high-salt feeding
and returned to baseline levels when the low-salt diet was insti-
tuted, consistent with the phenotype of sodium sensitivity previ-
ously reported in 129 mice (Francois et al., 2005); however, the
magnitude of BP difference between the PTKOs and controls re-
mained constant across the different dietary sodium intakes.
To exclude the possibility that vascular responses mediated
by AT1 receptors might be affected in the PTKOs, we assessed
acute pressor responses to angiotensin II in vivo as described
previously (Ito et al., 1995). As shown in Figure 1C, acute infusion
of angiotensin II causedmarked vasoconstriction and themagni-
tude of the vasoconstrictor responses was virtually identical in
both groups.AT1A Receptors in the Proximal Tubule Control Fluid
Reabsorption
To determine whether deletion of AT1A receptors would affect
fluid handling in the proximal tubule, we examined nephron470 Cell Metabolism 13, 469–475, April 6, 2011 ª2011 Elsevier Inc.function by using free-flow micropuncture (Hashimoto et al.,
2005). As shown in Table 1 and Figure 1D, absolute rates of prox-
imal fluid reabsorption (4.76 ± 0.32 versus 7.5 ± 0.58 nl/min;
p = 0.00014) were significantly reduced in the PTKOs compared
to controls. Single-nephron GFRs measured in the proximal
tubule were also significantly lower in the PTKOs (13 ± 0.61
nl/min) than controls (16.54 ± 0.81 nl/min; p = 0.001), consistent
with the whole-animal values (Table 1). Nonetheless, when cor-
rected for SNGFR, fractional reabsorption rates in the proximal
tubule were also significantly lower in the PTKOs (36.5 ± 1.5%)
than controls (44.5 ± 1.6%; p = 0.0005, Figure 1E). Thus, loss
of AT1A receptors from the proximal tubule leads to a reduction
in fluid reabsorption, indicating a tonic role for the RAS to control
fluid reabsorption by proximal tubule epithelia in vivo.PTKO Mice Are Protected Against Hypertension
To determine the contribution of AT1A receptors in the proximal
tubule to the development of hypertension, we infused PTKO
and control mice with angiotensin II (1000 ng/kg/min) by osmotic
Table 1. Physiological Data
Control (n = 8) PT KO (n = 7) p Value
Body weight (g) 32.4 ± 1.73 30 ± 1.54 ns
Kidney weight (mg) 435.4 ± 19.8 410 ± 22.1 ns
Glomerular filtration rate
(GFR, ml/min)
620 ± 49 439 ± 58 0.025
U Osm (mOsm/kg H2O) 2441.4 ± 103 2165 ± 102 0.15
UV (ml/min) 1.5 ± 0.08 2.1 ± 0.17 0.005
Proximal Tubule Micropuncture
TF/P iothal 1.85 ± 0.05 1.6 ± 0.03 0.0002
Absorption (nl/min) 7.5 ± 0.58 4.76 ± 0.32 0.000
Fractional abs (%) 44.45 ± 1.57 36.5 ± 1.53 0.0005
Data represent values ± SEM.
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Angiotensin Receptors in the Renal Proximal Tubuleminipump. As shown in Figure 2A, the control group developed
robust hypertension with a mean systolic BP of 172 ±
4 mm Hg, which was significantly higher than that of the PTKOs
(150 ± 4 mm Hg; p = 0.0005). A similar difference was observed
comparing the mean increase in BPs in the controls (38 ± 5 mm
Hg) with the PTKOs (23 ± 3 mm Hg; p = 0.0005) (Figure 2B).
Thus, deletion of AT1A receptors from the proximal tubule
conveyed substantial protection against hypertension. As shown100
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Figure 2. AT1A Receptors in the Proximal Tubule Promote Hypertensio
(A)With infusion of angiotensin II (Ang II, 1000 ng/kg/min), BPs increased significan
II was significantly attenuated in the PTKOs (**p < 0.001).
(B) Themean increase in BP during the angiotensin II infusion was significantly less
*p = 0.0005).
(C) Cumulative sodium balance was significantly lower in the PTKOs (n = 8) than
represent SEM.
Cin Figure 2C, the extent of positive sodium balance was signifi-
cantly reduced in PTKOs (0.33 ± 0.04 mmol) compared to
controls (0.50 ± 0.07 mmol; p = 0.046), consistent with facilitated
natriuresis as a mechanism for their resistance to hypertension.
Control of Renal Sodium Transporters by AT1A
Receptors in Proximal Tubule
To examine the molecular mechanisms responsible for the
attenuated hypertension and enhanced pressure natriuresis in
PTKOs, we measured abundance of key sodium transporters
along the nephron (Figure 3). At baseline, there were no differ-
ences in abundance of any of these transporters between
PTKOs and controls. However, during angiotensin II infusion,
significant differences in pool sizes of key transporters were
uncovered. In control mice, abundance of the sodium-proton
antiporter 3 (NHE3), the major sodium transporter in the proximal
tubule, fell by z30% during angiotensin II infusion (Figures 3A
and 3B). By contrast, in the PTKOs, abundance of NHE3 fell by
more than 50% (Figures 3A and 3B) to levels that were signifi-
cantly lower than controls (0.50 ± 0.06 versus 0.70 ± 0.09;
p = 0.01). In control mice, levels of the sodium phosphate
cotransporter (NaPi2) were unaffected by angiotensin II infusion
(Figures 3C and 3D), whereas NaPi2 protein levels decreased by
z36% in the PTKOs (p = 0.005).10 11 12 13
 (n=12)
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tly in both control and PTKOmice but the hypertensive response to angiotensin
in the PTKOs (23 ± 3mmHg) compared to controls (black bars; 38 ± 5mmHg,
controls (n = 7, *p = 0.046) during the first 3 days of Ang II infusion. Error bars
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Figure 3. Abundance of Sodium Transporters in Control and PTKO Mice
Protein levels of key transporters in kidneys of PTKO and control mice including NHE3 (A and B), NaPi2 (C and D), and NKCC2 (E and F) were measured by
western blot. Numbers below the blots indicate the mean ± SEM of the sample density normalized to the control baseline set (arbitrarily defined as 1.0). The
densitometry data are in bar graphs (B, D, and F), where * indicates p < 0.05.
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Angiotensin Receptors in the Renal Proximal TubuleAbundances of the sodium-potassium-two-chloride cotrans-
porter (NKCC2), a major sodium transporter downstream in the
thick ascending limb of the loop of Henle, were equivalent at
baseline in the two experimental groups (Figure 3) and fell to
a similar extent during angiotensin II infusion (Figures 3E and
3F). Similarly, total protein abundance of the b subunit epithelial
sodium channel (ENaCb) expressed from late distal nephron
through collecting ducts and the a1 subunit of the sodium-potas-
sium ATPase (Na,K-ATPase) expressed all along the nephron
were unaffected in PTKO mice (Figures S3A and S3B).DISCUSSION
The importance of AT1 angiotensin receptors in clinical medicine
is highlighted by the impressive cardiovascular benefits of angio-
tensin receptor blockers (ARBs). As antihypertensive agents,
these drugs are effective and well tolerated (Matchar et al.,
2008), ameliorating morbidity and mortality associated with
cardiovascular diseases (Brenner et al., 2001; Lewis et al.,
2001; Pfeffer et al., 2003; Yusuf et al., 2008). By inference, these
clinical studies indicate powerful contributions of AT1 receptors
to the pathogenesis of cardiovascular disease, hypertension,
and kidney damage. However, the specific cellular targets
responsible for their pathological actions cannot be identified472 Cell Metabolism 13, 469–475, April 6, 2011 ª2011 Elsevier Inc.from studies by using pharmacological inhibitors that block
AT1 receptors in all tissues.
The kidney has been suggested to play a predominant role in
BP control. Guyton hypothesized that the substantial capacity of
the kidney to excrete sodium provides a compensatory system
of virtually infinite gain to oppose processes, including increases
in peripheral vascular resistance, which would tend to increase
BP (Guyton, 1991). This hypothesis is supported by the genetic
studies of Lifton and associates linking Mendelian disorders
impacting BP homeostasis to genetic variants affecting salt
and water handling by the kidney (Lifton et al., 2001). On the
other hand, a series of recent studies have suggested that
vascular dysfunction alone may be sufficient to cause hyperten-
sion (Guilluy et al., 2010; Heximer et al., 2003; Michael et al.,
2008; Wirth et al., 2008). For example, studies by Guilluy and
associates indicate that elimination of Arhgef1, a Rho exchange
factor linked to AT1 receptor signaling, from smooth muscle
apparently results in a complete abrogation of hypertension
(Guilluy et al., 2010).
In previous studies, by using renal cross-transplantation we
found distinct and significant roles for AT1A receptor actions in
both the kidney and extrarenal tissues in BP homeostasis
(Crowley et al., 2005). In hypertension, however, receptors inside
the kidney played the dominant role, driving elevations in BP
as well as the development of cardiac hypertrophy (Crowley
Cell Metabolism
Angiotensin Receptors in the Renal Proximal Tubuleet al., 2006). This was due to direct actions of AT1 receptors in the
renal parenchyma, independent of aldosterone. Within the
kidney, AT1 receptors are widely expressed in vasculature, in
glomeruli, and by populations of epithelial cells across the
nephron (Bouby et al., 1997). Activation of AT1 receptors at any
or all of these sites could potentially impact BP regulation.
Actions of angiotensin II to influence solute transport along the
nephron have been well documented (Barreto-Chaves and
Mello-Aires, 1996; Cogan, 1990; Geibel et al., 1990; Levine
et al., 1996; Peti-Peterdi et al., 2002; Quan and Baum, 1998;
Schuster et al., 1984; Wang et al., 1996). We considered that
the population of AT1 receptors in the proximal tubule may
directly impact BP regulation because the major portion of the
glomerular filtrate is reabsorbed here (Weinstein, 2008) and
sodium transport by the proximal tubulemay be amajor determi-
nant of the pressure-natriuresis response (McDonough et al.,
2003). Furthermore, studies by Navar and Kobori have sug-
gested that the proximal tubule is a key site of an independently
regulated intrarenal RAS serving as a source of angiotensinogen
and angiotensin II, whichmay influence nephron function (Kobori
et al., 2007; Navar et al., 2002). The capacity for angiotensinogen
generated in the proximal tubule to affect blood pressure was
shown by Sigmund and associates in studies by using trans-
genic mice expressing human angiotensinogen and renin specif-
ically in the proximal tubule (Lavoie et al., 2004). On the other
hand, it has been suggested that the final adjustments of urinary
sodium excretion in the distal nephron are also important for
body fluid volume homeostasis (Meneton et al., 2004). In this
regard, most of the humanmutations with effects upon BP affect
fluid reabsorption in the distal portion of the nephron (Lifton
et al., 2001).
We generated mice with specific deletion of AT1A receptors
from epithelial cells in the proximal tubule by using the well-char-
acterized PEPCK-Cre mouse line, which induces excision of
floxed alleles from epithelial cells in the proximal but not distal
tubule (Higgins et al., 2007; Rankin et al., 2006). We find that
elimination of AT1A receptors from the proximal tubule causes
a significant reduction of baseline BP byz10 mm Hg. Notwith-
standing recent reports of dominant actions of vascular signaling
in BP control (Guilluy et al., 2010; Heximer et al., 2003; Michael
et al., 2008; Wirth et al., 2008), the low BPs in the PTKOs
occurred despite intact constrictor responses to angiotensin II
in the peripheral vasculature. This nonredundant role for AT1
receptors in the proximal tubule to determine BP level also
suggests there is tonic stimulation of these receptors in the
basal, euvolemic state consistent with previous studies showing
that acute administration of specific AT1 receptor blockers to
rats inhibits net proximal reabsorption (Thomson et al., 2006;
Xie et al., 1990). Similarly, we find that elimination of AT1A recep-
tors from the proximal tubule also reduces rates of fluid
reabsorption.
Agtr1a/ mice with global deletion of AT1A receptors have
exaggerated fluctuations in BP with extremes of dietary sodium
intake (sodium sensitivity) (Oliverio et al., 2000). Enhanced
sodium sensitivity is associated with absence of AT1A receptors
from the kidney, whereas elimination of receptors only from
extrarenal tissues does not affect this response (Crowley et al.,
2005). Despite their lower basal BPs, the magnitude of BP
changes during high- and low-salt feeding was very similar inCPTKOs and controls (Figure 1C). Thus, deletion of AT1A receptors
from the proximal tubule alone is not sufficient to generate
a phenotype of enhanced sodium sensitivity, indicating that
AT1 receptor pools at other sites, perhaps in the distal nephron
or renal vasculature, may control this response.
We find that elimination of AT1 receptors from the proximal
tubule provides significant protection against angiotensin
II-dependent hypertension, identifying this epithelial compart-
ment as a target of the RAS that is critical to the pathogenesis
of hypertension. Protection from hypertension is associated
with enhanced natriuresis and altered sodium balance, suggest-
ing that modulation of sodium handling is critical for these
actions. As discussed above, activation of AT1 receptors stimu-
lates fluid reabsorption in proximal tubules (Schuster et al., 1984;
Cogan, 1990) by triggering coordinate stimulation of the luminal
sodium-proton antiporter (NHE3) along with the basolateral
Na,K-ATPase (Cogan, 1990; Geibel et al., 1990). Levels and
localization of key sodium transporters in the proximal tubule
are modified during ACE inhibition, suggesting control of their
synthesis and cell trafficking by angiotensin II (Yang et al., 2007).
We examined the contributions of AT1 receptors in the prox-
imal tubule in isolation to regulate abundance of key sodium
transporters in vivo in the intact animal. Under basal conditions,
there were no statistically significant differences in major trans-
porter abundance between the groups, although the levels of
NHE3 tended to be lower in the PTKOs. In this setting, the
PTKO animals are in balance and their urinary excretion of
sodium reflects dietary intake. Therefore, it follows that their
transporter profiles would not differ dramatically from controls.
Further, because of their reduced BPs and GFRs, hemodynamic
factors such as changes in peritubular capillary pressures may
also influence sodium reabsorption in the PTKOs independent
of absolute levels of epithelial transporters. By contrast, the
regulation of luminal transporters by AT1A receptors in the prox-
imal tubule is clearly revealed when the steady state is abruptly
modified during chronic infusion of angiotensin II. With angio-
tensin II infusion there was a significant reduction in NHE3 within
the control group compared to baseline. Such attenuation of
NHE3 expression in response to BP elevation has been
described previously (McDonough et al., 2003) and may be
one mechanism facilitating natriuresis as pressure increases.
The further and significant reduction in NHE3 levels in the PTKOs
compared to controls is consistent with a lower threshold for
pressure natriuresis in these mice, supported by the differences
we observed in net sodium balance (Figure 2C). We also found
that NaPi2 expression during angiotensin II infusion is regulated
by AT1A receptors in the proximal tubule (Figure 3). Taken
together, these findings provide clear evidence for actions of
AT1A receptors in the proximal tubule to oppose adaptive reduc-
tions in key sodium transporters in the proximal tubule during
hypertension, with the net effect of impairing the pressure natri-
uresis response (Magyar and McDonough, 2000). When this
pathway is eliminated, the hypertensive response is attenuated
(Figures 2A and 2B), highlighting the power of mechanisms
controlling renal solute reabsorption in the proximal tubule to
determine BP levels.
In summary, our studies show that the epithelium of the prox-
imal tubule is a critical location for integrating signals to set the
level of intra-arterial pressure. This is accomplished thoughell Metabolism 13, 469–475, April 6, 2011 ª2011 Elsevier Inc. 473
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Angiotensin Receptors in the Renal Proximal Tubulemodulation of tubular fluid reabsorption and regulated expres-
sion of sodium transporter proteins. The RAS provides tonic
control of this pathway supporting BP independent of its
vascular actions. Furthermore, it is likely that other neurohor-
monal systems exploit these proximal tubular mechanisms for
physiological control (DiBona, 2005; Zeng et al., 2009; Zhang
et al., 2009). Our data suggest that effective inhibition of sodium
reabsorption in the renal proximal tubule could be a useful ther-
apeutic strategy in hypertension, supplementing the range of
diuretic agents currently used to target sodium reabsorption in
distal nephron segments. Our studies further suggest that
blockade of this pathway is probably a key component under-
lying the therapeutic efficacy of RAS antagonists in the treatment
of hypertension.EXPERIMENTAL PROCEDURES
Animals
Inbred 129/SvEv mice with a conditional Agtr1a allele were generated as
described in Supplemental Experimental Procedures. The Pepck-Cre trans-
gene was backcrossed more than 10 generations onto the 129/SvEv back-
ground. Mice were bred and maintained in the animal facility at the Durham
VA Medical Center according to NIH guidelines.BP Measurements in Conscious Mice
BPs were measured in conscious mice by using radiotelemetry as described
previously (Crowley et al., 2005).Sodium Balance Studies
Measurements of sodium balance were carried out as described previously
(Crowley et al., 2006) with individual metabolic cages and a gel diet containing
nutrients, water, and 0.1%w/w sodium (Nutra-Gel; Bio-Serv, Frenchtown, NJ).Micropuncture Studies
Mice were anesthetized and prepared for micropuncture studies as described
previously (Hashimoto et al., 2005). To determine nephron filtration and
absorption rates, we infused 125I iothalamate (Glofil, Questcor Pharmaceuti-
cals, Hayward, CA) at 40 mCi/hr. A blood sample was collected after 20–
25 min of equilibration and free-flow micropuncture was performed.Immunoblot Analysis
Levels of renal transporter proteins were determined as described previously
(Yang et al., 2007). Kidneys were decapsulated, individually homogenized, and
centrifuged and the supernatant homogenate was retained. A constant
amount of homogenate protein from each animal was denatured, resolved
on 7.5% SDS-polyacrylamide gels, and transferred to a single polyvinylidene
difluoride membrane (Millipore Immobilon-P). After blocking, blots were incu-
bated with specific antibodies (listed in Supplemental Experimental Proce-
dures). Sample amounts were determined to be in the linear range of detection
and signals were quantitated with the Odyssey Infrared Imaging System (LI-
COR, Lincoln, NE). Data for each protein were normalized to the mean of
expression in the control noninfused group defined as 1.0.Statistical Analysis
The values for each parameter within a group are expressed as the mean ± the
standard error of the mean (SEM). For comparisons between groups, statis-
tical significance was assessed by using ANOVA followed by unpaired t test
adjusted for multiple comparisons (normally distributed data) and the Mann-
Whitney U test was employed for nonparametric data. For comparisons within
groups, normally distributed variables were analyzed by a paired t test,
whereas nonparametric analysis was with the Wilcoxon signed rank test.
Normality was determined by using the Shapiro-Wilk W test.474 Cell Metabolism 13, 469–475, April 6, 2011 ª2011 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.cmet.2011.03.001.
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